HEAD AND NECK SQUAMOUS CELL CARCINOMA

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. About 100 adults with cancer…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Zumutor Biologics Inc. • Aim: Disease control

Last updated Jun 16, 2026 20:33 UTC

New drug targets tough cancers in early trial

This study tests a new drug called ALE.P02 in people with advanced squamous cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to find and attack cancer cells that have a specific protein (Claudin-1). The main goals are to check safety, find the best d…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control

Last updated Jun 16, 2026 12:54 UTC

New antibody drug enters first human tests for hard-to-treat cancers

This early-phase study tests a new drug called CHS-114 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein on certain immune cells to help the body fight cancer. About 87 adults will take part to find safe doses and…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control

Last updated Jun 16, 2026 12:53 UTC

New hope for head and neck cancer: experimental drug faces final test

This study tests a new drug called petosemtamab against standard treatments in 600 people with advanced head and neck cancer that has spread or come back and cannot be cured. Participants must have already tried immunotherapy and chemotherapy. The goal is to see if petosemtamab h…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated Jun 16, 2026 12:53 UTC

Could a Sugar-Blocker boost immunotherapy in tough cancers?

This study tests whether adding an experimental drug (GB1211) to a standard immunotherapy (pembrolizumab) helps shrink tumors better than immunotherapy alone in people with advanced melanoma or head and neck cancer. About 92 adults whose cancer has spread or cannot be removed wil…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control

Last updated Jun 16, 2026 12:52 UTC

New drug combo targets Hard-to-Treat cancers in early trial

This study tests an experimental oral drug called VMD-928, given alone or with pembrolizumab, in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. About 242 peop…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control

Last updated Jun 15, 2026 19:09 UTC

New drug targets Hard-to-Treat cancers in early trial

This study tests a new drug called LY4052031 in people with advanced or metastatic solid tumors, including bladder, breast, and lung cancers. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The trial has two parts: first to find the safest dose, th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated Jun 15, 2026 19:09 UTC

New drug IDE034 targets Hard-to-Treat cancers in early trial

This study tests an experimental drug called IDE034 in adults with advanced solid tumors that have not responded to standard treatments. The drug targets two markers (B7-H3 and PTK7) found on certain cancer cells. The main goals are to check safety, find the best dose, and see if…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control

Last updated Jun 15, 2026 19:09 UTC

New combo therapy aims to fight HPV head and neck cancer before standard treatment

This study tests a new drug called CUE-101, alone or with another drug (pembrolizumab), in 30 people with newly diagnosed HPV-16 positive head and neck cancer that cannot be easily removed with surgery. The goal is to see if these drugs can boost the immune system to fight the ca…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

New drug targets Hard-to-Treat cancers with genetic weakness

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

New immune drug AZD6750 targets Hard-to-Treat cancers

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

New drug duo aims to fight advanced head and neck cancer

This study tests two experimental drugs, SYS6010 and Enlonstobart, in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors and how safe it is. About 70 adults who have not had prior treatment for advanced disease w…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

New hope for hard-to-treat head and neck cancer?

This study tests a new drug called SIBP-03 combined with cetuximab in people with advanced head and neck cancer that has come back or spread. It is for patients who have already tried standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination c…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Disease control

Last updated Jun 15, 2026 19:07 UTC

New injection therapy targets Hard-to-Treat cancers in early trial

This early-phase study tests an experimental drug called ONM-501, injected directly into tumors, either alone or with a second drug (cemiplimab), in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find the safes…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: OncoNano Medicine, Inc. • Aim: Disease control

Last updated Jun 15, 2026 19:06 UTC

Could Low-Dose radiation boost cancer treatment before surgery?

This study looks at whether adding a small amount of radiation to standard targeted therapy and immunotherapy before surgery can help shrink head and neck tumors more effectively. About 98 adults with operable head and neck squamous cell carcinoma will be randomly assigned to rec…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control

Last updated Jun 15, 2026 19:04 UTC

New drug combo shows promise in shrinking head and neck tumors before surgery

This study tests whether giving two drugs (pembrolizumab and IO102-103) before surgery is safe and effective for people with head and neck cancer. About 30 adults with removable tumors will receive the combination and then have surgery. Researchers will monitor side effects and c…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated Jun 15, 2026 19:03 UTC

New pill takes on Hard-to-Treat cancers in first human trial

This study tests a new daily pill, VLS-1488, in 200 adults with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow cancer growth. It is an early-phase trial focused on safety and dosing,…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control

Last updated Jun 15, 2026 18:57 UTC

New cancer drug shows promise in early human trial

This study tests a new experimental drug called SIM0610 in adults with advanced solid tumors that have spread. The main goals are to check the drug's safety and find the right dose. About 260 people with cancers like lung, colorectal, head and neck, or liver cancer will take part…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 15, 2026 18:56 UTC

New radiation drug targets Hard-to-Treat cancers in first human trial

This early-phase study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to other treatments. The main goals are to check safety and find the best dose. A…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 15, 2026 18:55 UTC

Engineered immune cells take on Hard-to-Treat cancers

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Anusha Kalbasi • Aim: Disease control

Last updated Jun 15, 2026 18:55 UTC

Engineered immune cells take aim at Hard-to-Treat cancers in early trial

This early-phase study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). The treatment uses a patient's own immune cells, whi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 15, 2026 18:55 UTC

Could a Two-Drug punch before surgery shrink head & neck tumors?

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 12, 2026 12:08 UTC

New vaccine-immunotherapy combo aims to boost cancer fight before surgery

This study tests a new treatment for people with a type of head and neck cancer that can be removed by surgery. The treatment combines an experimental vaccine (IMP3-Mito) with immunotherapy drugs, given before and after surgery. The goal is to see if this combination can kill mor…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control

Last updated Jun 12, 2026 12:08 UTC

New virus therapy takes on advanced cancers in first human trial

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 12, 2026 12:06 UTC

New hope for head and neck cancer: cetuximab after failed immunotherapy

This study is for people with head and neck cancer that has come back or spread. It tests whether the drug cetuximab can shrink tumors when given alone after immunotherapy (PD-1 inhibitors) stops working or causes side effects. About 38 adults will take part. The goal is to see h…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control

Last updated Jun 12, 2026 12:02 UTC

Targeted radiation drug takes aim at Hard-to-Treat cancers

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 11, 2026 12:10 UTC

New hope for head and neck cancer: experimental combo shows promise

This study tests a new combination of drugs (SI-B001 and SI-B003) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this combination can shrink tumors or slow the disease. About 60 adults aged 18 to 75 …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 11, 2026 12:10 UTC

New hope for recurrent head and neck cancer: drug combo with Re-Radiation enters human testing

This study tests a combination of two drugs (tislelizumab and pamiparib) plus chemotherapy and a second round of radiation in people whose head and neck cancer has returned after prior treatment. The main goal is to find the safest dose and see how well the body tolerates the tre…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control

Last updated Jun 11, 2026 11:57 UTC

New combo therapy aims to boost survival in head and neck cancer

This study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer. About 700 adults with PD-L1 positive cancer that has spread or come back will receive either the combination or pembrolizumab alon…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated Jun 10, 2026 13:28 UTC

New drug targets 'Undruggable' cancer mutation in early trial

This early-phase study tests a new drug, CLSP-1025, for people with advanced solid tumors that have a specific change in the p53 gene (R175H) and a certain immune type (HLA-A*02:01). The drug is designed to help the immune system attack these cancer cells. The study aims to find …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control

Last updated Jun 10, 2026 13:28 UTC

New drug EPI-326 targets tough cancers in early human trial

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also see if the drug helps shrink tumors.

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control

Last updated Jun 10, 2026 13:25 UTC

DNA vaccine takes on HPV head and neck cancer

This study tests a combination of a DNA vaccine (GX-188E), an immune booster (GX-I7), and an immunotherapy drug (nivolumab) in 21 adults with HPV 16- or 18-positive head and neck cancer that has spread or returned after platinum chemotherapy. The goal is to see if the combination…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control

Last updated Jun 10, 2026 13:24 UTC

New hope for tough cancers: experimental drug DR-0202 enters human testing

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or prostate cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Dren Bio • Aim: Disease control

Last updated Jun 09, 2026 12:08 UTC

New drug duo aims to shrink head and neck tumors

This study tests whether a combination of two drugs, ACR-368 and low-dose gemcitabine, can shrink tumors or slow cancer growth in people with head and neck cancer that has come back or spread. About 43 adults will receive the drugs every two weeks. The goal is to see if the treat…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control

Last updated Jun 09, 2026 12:07 UTC

Could less radiation be enough for head and neck cancer?

This study is testing a new approach for people with certain head and neck cancers: using lower doses of radiation and chemotherapy, followed by surgery to remove any remaining cancer in the neck. The goal is to see if this gentler treatment can still control the cancer while red…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 08, 2026 13:17 UTC

New virus therapy targets Hard-to-Treat cancers in first human trial

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with another drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals a…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control

Last updated Jun 08, 2026 13:12 UTC

Could a drug cocktail before surgery spare head and neck cancer patients from radiation?

This study is for people with a type of head and neck cancer that can be removed with surgery. Researchers want to see if adding two immunotherapy drugs (cemiplimab and cetuximab) to standard chemotherapy before surgery is safe, and if it might help patients avoid radiation thera…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 08, 2026 13:12 UTC

New pill takes on brain tumors and metastases in early trial

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control

Last updated Jun 08, 2026 13:05 UTC

New drug BL-B01D1 targets Hard-to-Treat cancers in early trial

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 470 adults will take part.

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control

Last updated Jun 08, 2026 13:04 UTC

New drug trial offers hope for Hard-to-Treat head and neck cancers

This early-phase study tests a new drug called BL-M24D1 in people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 16 adults aged 18 to 75 will ta…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 08, 2026 13:03 UTC

New drug combo aims to shrink Hard-to-Treat tumors

This early-stage trial tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and check for early signs of tumor shrinkage. A…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control

Last updated Jun 02, 2026 11:58 UTC

Blood test may help personalize chemo for head and neck cancer patients

This study tests whether a blood test that tracks tumor DNA can help doctors decide when to add short bursts of chemotherapy to standard immunotherapy for people with recurrent or metastatic head and neck cancer. About 30 adults will receive the immunotherapy drug pembrolizumab, …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control

Last updated Jun 01, 2026 18:03 UTC

Off-the-Shelf immune cells take on Hard-to-Treat cancers

This early-stage study tests a new cancer treatment called FT836, a type of immune cell that is made in a lab and ready to use (off-the-shelf). It is given to people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control

Last updated Jun 01, 2026 17:55 UTC

Could skipping chemo after head and neck cancer surgery be just as effective?

This study looks at whether adding the chemotherapy drug cisplatin to standard radiation therapy helps prevent head and neck cancer from coming back after surgery. About 189 people with stage III or IVA squamous cell carcinoma of the head and neck will take part. Researchers will…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control

Last updated May 27, 2026 23:06 UTC

New drug CTX-8371 tested in patients with advanced cancers

This early-stage study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck,…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control

Last updated May 26, 2026 11:09 UTC

Glow-in-the-Dark dye could help surgeons find hidden tumors

This study tests a fluorescent dye called pegsitacianine that makes cancer cells glow during surgery. About 120 adults with head and neck cancer will receive one dose before their operation. Doctors will use special cameras to see if the dye helps find tumors that are hard to spo…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis

Last updated Jun 16, 2026 12:55 UTC

New radioactive tracer could spot hidden cancer in neck lymph nodes

This early-stage trial tests whether a radioactive drug called 111In-panitumumab can help doctors find the first lymph nodes where head and neck cancer has spread. About 30 adults with head and neck cancer scheduled for surgery will receive the drug and then get a special scan (S…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Jun 15, 2026 19:07 UTC

New imaging combo could help surgeons spot hidden cancer during surgery

This early-phase trial is testing whether combining two imaging techniques can help surgeons find and remove head and neck cancer more completely. About 40 adults with head and neck cancer will receive a special radioactive dye before surgery, followed by a fluorescent dye during…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Jun 15, 2026 19:03 UTC

New scan could spot hidden cancer spread in head and neck patients

This study tests a new imaging agent called 89Zr panitumumab to see if it can more accurately find cancer that has spread in people with head and neck cancer. Standard PET/CT scans often miss or wrongly identify these spots. About 60 participants will receive the new agent and th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis

Last updated Jun 11, 2026 12:11 UTC

New PET tracer could slash unnecessary biopsies for head and neck cancer patients

Prevention Recruiting now

This early-phase study tests a new radioactive tracer called [18F]NOTA-ABY030, which is designed to make head and neck squamous cell carcinoma show up more clearly on PET/CT scans. About 25 adults with suspicious or unclear findings on standard scans will receive the tracer and b…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Jun 10, 2026 13:29 UTC

Ice microneedle patch may stop radiation skin damage in cancer patients

This early-phase study tests whether a protein called CFH, delivered through ice microneedles, can safely prevent radiation-induced skin fibrosis (hardening and scarring) in people with head and neck cancer. Nine participants will receive the patch twice a week during their radia…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: West China Hospital • Aim: Prevention

Last updated May 22, 2026 13:54 UTC

Fat flap may ease neck pain after cancer treatment

This study tests whether a buried fat flap procedure is safe and helpful for people who have neck problems like pain, stiffness, or trouble swallowing after head and neck cancer treatment. About 12 adults who need a second neck surgery will get the flap and be followed for compli…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief

Last updated Jun 16, 2026 20:34 UTC

Heat boost: new combo therapy aims to shrink incurable tumors

This study tests whether adding a special heat treatment (water-filtered infrared, or wIRA) to standard palliative radiation can help shrink tumors and ease symptoms in people with advanced head, neck, or skin cancer that cannot be cured. About 60 adults will receive the combined…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: King's College London • Aim: Symptom relief

Last updated Jun 16, 2026 12:49 UTC

Can a constipation drug help head and neck cancer patients before surgery?

This study tests whether a drug called methylnaltrexone is safe for people with head and neck cancer when taken for two weeks before their surgery. The drug is already used for constipation, but researchers want to see if it can be given safely in this setting. About 25 adults wi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Jun 15, 2026 19:03 UTC

New drug aims to prevent painful mouth sores in head and neck cancer treatment

This study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside usual mouth rinses and pain medications. The goal is to impro…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief

Last updated Jun 15, 2026 18:57 UTC

Can a nutrition drink ease chemo side effects? new study aims to find out

This study tests whether a special nutrition supplement can reduce severe side effects from standard cancer treatments in people with head and neck, lung, or rectal cancer. About 52 participants will take the supplement during their treatment, and their results will be compared t…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Symptom relief

Last updated Jun 15, 2026 18:57 UTC

Shorter radiation may bring faster relief for head and neck cancer patients

This study tests whether a shorter course of high-precision radiation (SBRT) can safely reduce symptoms in people with head and neck cancer that cannot be cured. About 108 adults whose cancer has returned or spread will receive either standard or shorter radiation. The goal is to…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Jun 12, 2026 12:07 UTC

Olanzapine may help head and neck cancer patients eat better during chemoradiation

This study looks at whether adding olanzapine to standard nausea care can help head and neck cancer patients maintain their appetite and weight during chemoradiation. About 66 adults with head and neck cancer who are getting chemoradiation will take olanzapine or a placebo alongs…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief

Last updated Jun 11, 2026 12:10 UTC

New hope for cancer patients: drug may replace opioids for mouth sore pain

This study tests whether a high dose of gabapentin, a non-opioid pain medicine, can prevent the need for opioid painkillers in people with head and neck cancer who develop painful mouth sores from chemotherapy and radiation. About 228 participants will be randomly assigned to rec…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief

Last updated Jun 11, 2026 12:09 UTC

Heavy lifting may help cancer survivors rebuild strength

This study tests whether a heavy lifting strength training program is safe and helpful for people who have finished treatment for head and neck cancer at least one year ago. Researchers want to see if it improves muscle strength, physical function, fatigue, and quality of life co…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Alberta • Aim: Symptom relief

Last updated Jun 08, 2026 13:05 UTC

New MRI study aims to personalize radiation for head and neck cancer

This study looks at how head and neck cancers change during radiation therapy by using repeated MRI scans. Researchers want to learn which parts of the tumor are most resistant, so future treatments can be more targeted. About 173 people with newly diagnosed head and neck cancer,…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused

Last updated Jun 16, 2026 12:52 UTC

New program aims to speed up cancer treatment after surgery

This study tests a program called ENDURE that helps head and neck cancer patients start radiation therapy within 6 weeks after surgery, as guidelines recommend. About 532 adults with certain types of head and neck cancer will take part. The program uses patient navigators to guid…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Medical University of South Carolina • Aim: Knowledge-focused

Last updated Jun 16, 2026 12:49 UTC

Virtual reality could make head and neck cancer surgery more precise

This study explores whether virtual reality and 3D models can help surgeons plan head and neck cancer operations more accurately. About 160 adults with head and neck cancer will take part. The goal is to see if this technology reduces the chance of leftover cancer cells and impro…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Thomas Jefferson University • Aim: Knowledge-focused

Last updated Jun 15, 2026 19:08 UTC

Blood test may spare throat cancer patients from unnecessary radiation

This study is for people with HPV-related throat cancer who have surgery to remove their tumor. Researchers want to see if a blood test that looks for leftover cancer DNA can tell who truly needs radiation afterward. If the test is negative after surgery, patients may skip radiat…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused

Last updated Jun 15, 2026 19:05 UTC

Mini-Tumors in a dish may guide cancer treatment choices

This study looks at whether tiny lab-grown copies of a patient's tumor (called organoids) can predict which drugs will work best for that person. Researchers will compare the organoid test results with how the patient actually responds to treatment. The goal is to see if this app…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Huashan Hospital • Aim: Knowledge-focused

Last updated Jun 15, 2026 19:04 UTC

Cancer nutrition study aims to improve treatment tolerance

This study follows 110 adults with head/neck, lung, or rectal cancer to see how their diet, muscle mass, and weight change during standard cancer therapy. Researchers will track food intake, body composition, and handgrip strength over time. The goal is to gather information that…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused

Last updated Jun 15, 2026 19:03 UTC

New imaging tracer lights up tumors in first human tests

This early-phase study is testing a new radioactive imaging agent in 32 adults with various solid tumors. The goal is to see how the agent spreads through the body and whether it can highlight tumors on PET/CT scans. Participants receive a single injection of the agent and underg…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Var2 Pharmaceuticals • Aim: Knowledge-focused

Last updated Jun 15, 2026 18:57 UTC

Blood test and gene clues may predict throat cancer return

This study is watching 220 people with HPV-related throat cancer to see if a blood test for HPV DNA and certain gene changes (TRAF3 and CYLD) can predict if the cancer will come back. Participants get standard treatment and follow-up scans. The goal is to learn, not to test a new…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused

Last updated Jun 15, 2026 18:56 UTC

Remote hearing tests could save cancer Patients' hearing

This study looks at whether offering hearing tests near home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy and radiation can cause hearing loss, but regular monitoring can catch it early. The study will enroll 118 a…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused

Last updated Jun 12, 2026 12:05 UTC

New imaging study reveals hidden vascular damage from radiation therapy